TGF-beta/Smad compound library

Catalog No.L5600

A unique collection of 156 small molecules with biological activity used for TGF-beta/Smad pathway research.

Customize Your Library:

Cited by 279 Publications

• A unique collection of 156 small molecule compounds for high throughput screening(HTS) and high content screening (HCS).

• Target includes TGF-beta/Smad, TGF-β Receptor, PKC, ROCK and RAS

• A useful tool for finding tumor therapeutic mechanism and new targets.

• For studying human diseases, exploring the pathogenesis of diseases such as cancer, and opening noval therapeutic ways.

• Structurally diverse, medicinally active, and cell permeable.

• Rich documentation with structure description, target information, IC50 values and customer reviews.

• NMR and HPLC validated to ensure high purity.

Formulation	150 compounds pre-dissolved in 10mM DMSO, 2 compounds pre-dissolved in 10mM water and 4 compounds pre-dissolved in 2mM DMSO
Container	96 Deep Well Plate Sealed With Aluminum Foil
Stability	12 months	-20°C	in DMSO
Stability	24 months	-80°C	in DMSO
Shipping	Blue ice or dry ice

Application of GPCR Compound Library in liver cancer (This article was published in Nature (IF=43) and took about 15 months):

Nature.2019;574(7777):268-272
Application of Kinase Inhibitor Library in colorectal cancer (This article was published in Nature Communications (IF=11) and took about 8 months):

Nat Commun. 2019 16;10(1):2197
Application of FDA-approved Drug Library in antivirus (This article was published in Cell Research (IF=17) and took about 13 months):

Cell Res. 2019;29(9):739-753
Application of FDA-approved Drug Library in metabolism (This article was published in Movement Disorders (IF=8) and took about 10 months):

Mov Disord. 2019;34(3):323-334
Application of Epigenetics Compound Library in acute lymphoblastic leukemia (This article was published in Blood (IF=16) and took about 16 months):

Blood. 2019 17;134(16):1323-1336
Application of Inhibitor Library in tumor immunology (This article was published in Cancer Immunol Res (IF=8.6) and took about 12 months):

Cancer Immunol Res.2017;5(9):790-803